David Loreck
University of Maryland, Baltimore
19 Papers
106 Citations
David Loreck is an academic researcher from University of Maryland, Baltimore. The author has contributed to research in topics: Dementia & Medicine. The author has an hindex of 14, co-authored 19 publications. Previous affiliations of David Loreck include Veterans Health Administration.
Chat about Author
Papers
Effect of Vitamin E and Memantine on Functional Decline in Alzheimer Disease The TEAM-AD VA Cooperative Randomized Trial
Maurice W. Dysken,Mary Sano,Sanjay Asthana,Julia E. Vertrees,Muralidhar Pallaki,Muralidhar Pallaki,Maria D. Llorente,Susan Love,Gerard D. Schellenberg,J. Riley McCarten,Julie Malphurs,Susana Prieto,Peijun Chen,Peijun Chen,David Loreck,David Loreck,George Trapp,Rajbir S. Bakshi,Jacobo Mintzer,Jacobo Mintzer,Judith L. Heidebrink,Ana Vidal-Cardona,Lillian M. Arroyo,Angel R. Cruz,Sally B. Zachariah,Neil W. Kowall,Mohit P. Chopra,Suzanne Craft,Stephen Thielke,Carolyn Turvey,Carolyn Turvey,Catherine Woodman,Catherine Woodman,Kimberly A. Monnell,Kimberly Gordon,Julie Tomaska,Yoav Segal,Peter Peduzzi,Peter Peduzzi,Peter Guarino,Peter Guarino +40 more
TL;DR: Benefit of alpha tocopherol in mild to moderate AD is suggested by slowing functional decline and decreasing caregiver burden.
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.
Somaia Mohamed,Somaia Mohamed,Gary R. Johnson,Peijun Chen,Paul B. Hicks,Paul B. Hicks,Lori L. Davis,Lori L. Davis,Jean Yoon,Theresa Gleason,Julia E. Vertrees,Kimberly R. Weingart,Kimberly R. Weingart,Ilanit Tal,Alexandra Scrymgeour,David Lawrence,Beata Planeta,Michael E Thase,Grant D. Huang,Sidney Zisook,Sidney Zisook,Sanjai D. Rao,Sanjai D. Rao,Patricia Pilkinton,James Wilcox,Ali Iranmanesh,Mamta Sapra,George Jurjus,James P. Michalets,Muhammed Aslam,Thomas P. Beresford,Keith D. Anderson,Ronald Fernando,Sriram Ramaswamy,John Kasckow,Joseph Westermeyer,Gihyun Yoon,D. Cyril D’Souza,Gunnar Larson,William G. Anderson,Mary Klatt,Ayman Fareed,Shabnam I. Thompson,Carlos J. Carrera,Solomon S. Williams,Timothy M. Juergens,Lawrence J. Albers,Clifford S. Nasdahl,Gerardo Villarreal,Julia L. Winston,Cristobal A. Nogues,K. Ryan Connolly,Andre Tapp,Kari A. Jones,Gauri Khatkhate,Sheetal Marri,Trisha Suppes,Joseph M. LaMotte,Robin A. Hurley,Aimee R. Mayeda,Alexander B. Niculescu,Bernard A. Fischer,David Loreck,Nicholas Rosenlicht,Steven Lieske,Mitchell S. Finkel,John T. Little +66 more
TL;DR: Among a predominantly male population with major depressive disorder unresponsive to antidepressant treatment, augmentation with aripiprazole resulted in a statistically significant but only modestly increased likelihood of remission during 12 weeks of treatment compared with switching to bupropion monotherapy.
Research consent for cognitively impaired adults: Recommendations for Institutional Review Boards and investigators
Constantine G. Lyketsos,Jason Brandt,Paul Fishman,Michael Gloth,Vassilis E. Koliatsos,David Loreck,Marsden McGuire,Peter V. Rabins,Debra S. Wertheimer,Jack Schwartz,Anand Das,Greg A. Sachs,Marilyn S. Albert,Stephen McConnell,William Thies +14 more
TL;DR: This document contains recommendations that IRBs and investigators can use to operationalize the informed consent process for individuals with cognitive impairment.
87
Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data
Maurice W. Dysken,Peter Guarino,Julia E. Vertrees,Sanjay Asthana,Mary Sano,Maria D. Llorente,Muralidhar Pallaki,Susan Love,Gerard D. Schellenberg,J. Riley McCarten,Julie Malphurs,Susana Prieto,Peijun Chen,David Loreck,Sara Carney,George Trapp,Rajbir S. Bakshi,Jacobo Mintzer,Judith L. Heidebrink,Ana Vidal-Cardona,Lillian M. Arroyo,Angel R. Cruz,Neil W. Kowall,Mohit P. Chopra,Suzanne Craft,Stephen Thielke,Carolyn Turvey,Catherine Woodman,Kimberly A. Monnell,Kimberly Gordon,Julie Tomaska,Govind T. Vatassery +31 more
TL;DR: A clinical trial was designed to compare the effectiveness of alpha‐tocopherol, a vitamin E antioxidant; memantine (Namenda), an N‐methyl‐D‐aspartate antagonist; their combination; and placebo in delaying clinical progression in AD.
Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism.
Juan Galarraga,David Loreck,Jon F. Graham,R L DeLaPaz,B H Smith,Douglas Hallgren,C. J. Cummins +6 more
TL;DR: Human glioma-derived cell cultures adequately reflect the metabolic capacity of gliomas in situ and are significantly altered in several aspects of their glycolytic metabolism.
48